Latest for Arrhythmogenic Cardiomyopathy
See all trialsThe week in rare diseaseEach date is the day a change was posted. Open an item to see where things stand now.
- Trial statusNow recruiting. Distribution of Cell-cell Junction Proteins in Arrhythmic Disorders (St. George's Hospital, London)ClinicalTrials.gov
More about Arrhythmogenic Cardiomyopathy
These mutations impair intercellular adhesion, leading to myocyte death and replacement by fibrous and fatty tissue. Progressive conduction system disease develops with altered electrical properties facilitating re-entrant arrhythmias.
Keep reading about Arrhythmogenic Cardiomyopathy
Patients present with palpitations and syncope from ventricular arrhythmias, or catastrophically with sudden cardiac death. Characteristic ECG findings include epsilon waves (small electrical deflections after QRS), low QRS voltages, and T wave inversions in anterior leads. Cardiac imaging shows right ventricular dilatation and regional wall motion abnormalities with intramural fat infiltration visible on cardiac MRI. Arrhythmias are often exercise-induced and may be exercise-triggered, making risk stratification critical. Progressive disease leads to biventricular involvement and congestive heart failure.
What are the symptoms of Arrhythmogenic Cardiomyopathy?
These are common symptoms of Arrhythmogenic Cardiomyopathy, and how strong they are varies from person to person.
- Palpitations and syncope from arrhythmias
- Epsilon waves on ECG
- Sudden cardiac death risk
- Progressive dyspnea and fatigue
- Right ventricular dysfunction on imaging
- Atrial fibrillation
Who gets Arrhythmogenic Cardiomyopathy?
Arrhythmogenic cardiomyopathy often manifests in adolescence or early adulthood with palpitations or syncope, though disease presentation varies considerably. Some individuals remain asymptomatic and are identified through family screening.
The condition affects males and females, though males are at notably higher risk for sudden cardiac death. Autosomal dominant inheritance is most common, with approximately 50% of offspring of affected parents inheriting mutations. Rare autosomal recessive forms exist, particularly in populations with consanguinity.
Next steps: find trials you might fitsee what is being testedget help payingget alerts
Which new Arrhythmogenic Cardiomyopathy medicines are in trials?
Investigational medicines Trial Friend tracks for Arrhythmogenic Cardiomyopathy, with trial results, safety findings and where each one stands.
How to get help paying for Arrhythmogenic Cardiomyopathy treatment
Charity funds and drugmaker programs for Arrhythmogenic Cardiomyopathy, checked at the source.
No charity fund for this condition is open right now. Funds reopen when they receive new donations; the foundations let you sign up to be told when one opens.
Side effects people have reported to the FDA
Side effects people have reported to the FDA
Real-world side effect reports from the FDA Adverse Event Reporting System (FAERS). Includes both FDA-approved drugs and investigational therapies from active clinical trials. Click any drug to see what patients reported.
Loading side effect data...
Diagnosis and genetic testing
Genetic testing for Arrhythmogenic Cardiomyopathy
Genetic testing can confirm a diagnosis, guide treatment decisions, and identify family members who may be at risk.
Finding labs...
Trusted Arrhythmogenic Cardiomyopathy resources
Reputable organizations and medical references for learning more about Arrhythmogenic Cardiomyopathy, including disease registries, foundation resources, and clinical guidelines.